Leiomyosarcoma

Ankit Mangla; Udit Yadav.

Author Information

Last Update: May 14, 2022.

Go to:

Continuing Education Activity

This activity reviews the evaluation, diagnosis, treatment, and latest advances in the field of leiomyosarcoma. It will discuss the existing literature and present the most recent evidence regarding treatment options available for patients diagnosed with soft-tissue sarcoma/leiomyosarcoma. It will also review the ongoing phase I-II trials and medications currently under evaluation to treat soft-tissue sarcoma/leiomyosarcoma. This activity will also highlight the interprofessional team’s role in managing leiomyosarcoma to optimize patient outcomes.

Objectives:

  • Identify the etiology of leiomyosarcoma.
  • Outline the management options available for leiomyosarcoma.
  • Summarize the latest molecules and clinical trials exploring treatment options for all soft-tissue sarcoma, including leiomyosarcoma.
  • Explain interprofessional team strategies for improving care coordination and communication to advance leiomyosarcoma and improve outcomes.

https://www.ncbi.nlm.nih.gov/books/NBK551667/

Non-Uterine Research Updates-

Soft Tissue Sarcoma

 

PRESS RELEASE NEWS  from Dr. Brian Van Tine about UNESBULIN: for LMS:  
https://ir.ptcbio.com/…/preliminary-results-presented…Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

Article by Dr. Matthew Hemming in the Journal of TRANSLATIONAL CANCER MECHANISMS AND THERAPY|JUNE 01 2022

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression 
https://aacrjournals.org/clincancerres/article-abstract/28/11/2397/698931/Preclinical-Modeling-of-Leiomyosarcoma-Identifies?redirectedFrom=fulltext

Surgical management strategy for leiomyosarcoma of Zone I-II inferior vena cava: A case series     https://pubmed.ncbi.nlm.nih.gov/35665732/

Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study:  
https://pubmed.ncbi.nlm.nih.gov/36857355/

 
Jonathan Trent, MD, PhD. Sylvester Comprehensive Cancer Center, Sarcoma Center, Miami, FL

Presentation to the Patient – Family Advocacy Network:  Use of Trabectedin in the Treatment of LMS (29 Jan 2023) Hosted by the NLMSF.
Video recording: https://youtu.be/efuZXkaRncQ

Annie Achee, NLMSF Empowering patients through information / educaiton / support

2022:

2021:

2020:

2019: 

2018: